These findings represent previously unidentified druggable vulnerabilities in CDH1−/− cells and may lead to the development of a novel chemopreventative approach for the management of HDGC, or novel therapies for sporadic E-cadherin-deficient cancers. The gene discussed is CDH1; the disease is cancer.